Go to deals
Healthcare | Private Equity

Medicharme has sold a majority stake to G Square

Medicharme has completed a growth capital transaction backed by G Square, a UK-based private equity fund dedicated to Healthcare investments.

Medicharme is a French geriatric care facilities operator. It owns 15 long-term care nursing homes in France, with nearly 1,000 beds.

G Square is a British leading healthcare private equity investor, focusing on European mid-market projects with a high potential for growth. G Square provides between US$35–70 million of equity in each healthcare investment deal. the firm will support Medicharme's ambitious development plan to operate 2,500 beds within the next five years.

Oaklins' team in France assisted Medicharme in this transaction.

Parties

Talk to the deal team

Thibaut de Monclin

Managing Partner
Paris, France
Oaklins France

Related deals

Afric Phar has been acquired by Pharma Capital
Healthcare

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Learn more
Den Berk Délice accelerates growth through strategic partnership
Private Equity | Agriculture

Den Berk Délice accelerates growth through strategic partnership

Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.

Learn more
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Learn more